BACKGROUND: There are only scarce data about the benefit of adjunctive chemotherapy in patients with localized synovial sarcoma (SS). PATIENTS AND METHODS: Data from 237 SS patients recorded in the database of the French Sarcoma Group were retrospectively analyzed. The respective impact of radiotherapy, neo-adjuvant chemotherapy and adjuvant chemotherapy on overall survival (OS), local recurrence-free survival (LRFS) and distant recurrence-free survival (DRFS) were assessed after adjustment to prognostic factors. RESULTS: The median follow-up was 58 months (range 1-321). Adjuvant, neo-adjuvant chemotherapy and postoperative radiotherapy were administered in 112, 45 and 181 cases, respectively. In all, 59% of patients treated with chemotherapy received an ifosfamide-containing regimen. The 5-year OS, LRFS and DRFS rates were 64.0%, 70% and 57%, respectively. On multivariate analysis, age >35 years old, grade 3 and not-R0 margins were highly significant independent predictors of worse OS. After adjustment to prognostic factors, radiotherapy significantly improved LRFS but not DRFS or OS. Neither neo-adjuvant nor adjuvant chemotherapy had significant impact on OS, LRFS or DRFS. CONCLUSION: As for other high-grade soft-tissue sarcomas, well-planned wide surgical excision with adjuvant radiotherapy remains the cornerstone of treatment for SS. Neo-adjuvant or adjuvant chemotherapy should not be delivered outside a clinical trial setting.
BACKGROUND: There are only scarce data about the benefit of adjunctive chemotherapy in patients with localized synovial sarcoma (SS). PATIENTS AND METHODS: Data from 237 SS patients recorded in the database of the French Sarcoma Group were retrospectively analyzed. The respective impact of radiotherapy, neo-adjuvant chemotherapy and adjuvant chemotherapy on overall survival (OS), local recurrence-free survival (LRFS) and distant recurrence-free survival (DRFS) were assessed after adjustment to prognostic factors. RESULTS: The median follow-up was 58 months (range 1-321). Adjuvant, neo-adjuvant chemotherapy and postoperative radiotherapy were administered in 112, 45 and 181 cases, respectively. In all, 59% of patients treated with chemotherapy received an ifosfamide-containing regimen. The 5-year OS, LRFS and DRFS rates were 64.0%, 70% and 57%, respectively. On multivariate analysis, age >35 years old, grade 3 and not-R0 margins were highly significant independent predictors of worse OS. After adjustment to prognostic factors, radiotherapy significantly improved LRFS but not DRFS or OS. Neither neo-adjuvant nor adjuvant chemotherapy had significant impact on OS, LRFS or DRFS. CONCLUSION: As for other high-grade soft-tissue sarcomas, well-planned wide surgical excision with adjuvant radiotherapy remains the cornerstone of treatment for SS. Neo-adjuvant or adjuvant chemotherapy should not be delivered outside a clinical trial setting.
Authors: Da-Xian Luo; Mei-Juan Huang; Bo Xiong; Tao Li; Ke Xie; Fu-Rong Chen; Guo-Wei Che; Jin Wang; Yong Xu; Xiao-Juan Zhou; You Lu Journal: Interact Cardiovasc Thorac Surg Date: 2013-09-11
Authors: William G Kraybill; Jonathan Harris; Ira J Spiro; David S Ettinger; Thomas F DeLaney; Ronald H Blum; David R Lucas; David C Harmon; G Douglas Letson; Burton Eisenberg Journal: Cancer Date: 2010-10-01 Impact factor: 6.860
Authors: Kevin B Jones; Malay Haldar; Joshua D Schiffman; Lisa Cannon-Albright; Stephen L Lessnick; Sunil Sharma; Mario R Capecchi; R Lor Randall Journal: Cancer Control Date: 2011-07 Impact factor: 3.302
Authors: Zhengfu Fan; Shreyaskumar Patel; Valerae O Lewis; B Ashleigh Guadagnolo; Patrick P Lin Journal: Clin Orthop Relat Res Date: 2015-07-22 Impact factor: 4.176
Authors: C Chakiba; P Lagarde; D Pissaloux; A Neuville; C Brulard; G Pérot; J M Coindre; P Terrier; D Ranchere-Vince; A Ferrari; P Collini; A J H Suurmeijer; J Y Blay; S A Terrisse; S Piperno-Neumann; G Averous; B Bui; D Orbach; A Italiano; F Chibon Journal: Ann Oncol Date: 2014-07-28 Impact factor: 32.976